Zudena (udenafil) is a phosphodiesterase type 5 (PDE5) inhibitor specifically developed for the treatment of erectile dysfunction (ED). As a selective and potent agent, it offers a reliable therapeutic option with a favorable pharmacokinetic profile, supporting both spontaneous and planned intimacy. Its mechanism of action enhances blood flow to the corpus cavernosum, facilitating achievement and maintenance of erection upon sexual stimulation. Prescribed under medical supervision, Zudena represents an advancement in ED management, balancing efficacy, safety, and patient convenience.

Features

• Active ingredient: Udenafil 100 mg
• Pharmacological class: Phosphodiesterase type 5 (PDE5) inhibitor
• Onset of action: As early as 30 minutes post-administration
• Duration of effect: Up to 12 hours
• Administration: Oral tablet, taken with or without food
• Manufacturer compliance: GMP-certified production
• Packaging: Blister packs ensuring stability and authenticity

Benefits

• Provides a extended window of opportunity for sexual activity, reducing time-related pressure.
• Demonstrates high efficacy in improving erectile function across various ED severities and etiologies.
• Offers flexibility with or without food intake, enhancing patient adherence and convenience.
• Exhibits a favorable safety profile with low incidence of severe adverse events.
• Supports both spontaneous and planned intimate moments due to its rapid onset and prolonged duration.
• Contributes to improved patient and partner satisfaction, and overall quality of life.

Common use

Zudena is indicated for the treatment of erectile dysfunction in adult males. It is suitable for patients with ED of various origins, including organic, psychogenic, or mixed etiology. Clinical use is supported by evidence demonstrating improvement in the International Index of Erectile Function (IIEF) scores. It is not intended for use in women, children, or adolescents, and does not protect against sexually transmitted infections.

Dosage and direction

The recommended dose is 100 mg taken orally approximately 30–60 minutes before anticipated sexual activity. Dosage may be adjusted based on efficacy and tolerability, under physician guidance; however, the maximum recommended dosing frequency is once per day. Tablets should be swallowed whole with a glass of water. Sexual stimulation is required for the medication to be effective.

Precautions

Prior to prescribing Zudena, cardiovascular status should be assessed, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical deformation of the penis, bleeding disorders, or active peptic ulceration. Avoid concomitant use with other ED treatments. Patients should not use Zudena if sexual activity is inadvisable due to underlying health conditions. Regular follow-up is recommended to evaluate continued need and tolerance.

Contraindications

Zudena is contraindicated in patients with known hypersensitivity to udenafil or any excipients. Concomitant use with organic nitrates or nitric oxide donors in any form is strictly prohibited due to the risk of severe hypotension. It is also contraindicated in patients with severe hepatic impairment, end-stage renal disease requiring dialysis, hereditary degenerative retinal disorders, or a history of non-arteritic anterior ischemic optic neuropathy (NAION).

Possible side effects

Common adverse reactions include headache, flushing, nasal congestion, dyspepsia, and dizziness. These are generally mild to moderate and transient. Less frequently, visual disturbances (such as changes in color perception), back pain, myalgia, and palpitations may occur. In rare instances, priapism (prolonged erection >4 hours) requires immediate medical attention to prevent permanent damage. Sudden hearing decrease or loss has been reported in association with PDE5 inhibitor use.

Drug interaction

Zudena is primarily metabolized by CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase udenafil exposure—dose adjustment or avoidance is advised. Alpha-blockers and antihypertensives may potentiate hypotensive effects. Avoid use with other PDE5 inhibitors. Grapefruit juice may increase plasma concentrations and should be avoided. Always inform the prescribing physician of all current medications, including over-the-counter and herbal products.

Missed dose

Zudena is taken on an as-needed basis; therefore, the concept of a “missed dose” does not apply. Do not take an extra dose to make up for a missed opportunity. The next dose should be taken as planned before subsequent sexual activity, adhering to the once-daily maximum.

Overdose

In case of suspected overdose, standard supportive measures should be employed. Expected effects may mirror adverse reactions at an increased severity, such as severe hypotension, syncope, or prolonged erection. Priapism requires urgent urological intervention. Hemodialysis is not expected to significantly eliminate udenafil due to high protein binding and extensive tissue distribution.

Storage

Store at room temperature (15–30°C / 59–86°F) in the original packaging, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or making changes to your treatment plan. Do not disregard or delay seeking professional medical advice based on content provided here.

Reviews

Clinical studies and post-marketing surveillance indicate high patient satisfaction with Zudena, particularly noting its extended duration of action and reliability. Many users report improved confidence and relationship satisfaction. Healthcare professionals appreciate its predictable pharmacokinetics and manageable side effect profile. Individual experiences may vary; always follow your physician’s recommendations for safe and effective use.